思路迪医药
3D Medicines

3D Medicines Inc.
思路迪医药股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1244)

VOLUNTARY ANNOUNCEMENT

Early Completion of Enrollment in the Phase III Clinical Trial of Envafolimab for Neoadjuvant/Adjuvant Treatment of Non-Small Cell Lung Cancer

This announcement is made by 3D Medicines Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The board of directors of the Company (the "**Board**") is pleased to announce that the randomized, controlled, double-blind, multi-center Phase III clinical trial (Study No.: KN035-CN-017) of Envafolimab® (generic name: Envafolimab Injection, research code: KN035), co-developed by the Company and Alphamab Oncology (stock code: 9966.HK), for the neoadjuvant/adjuvant treatment of patients with resectable non-small cell lung cancer ("**NSCLC**") has successfully completed enrollment ahead of schedule.

This Phase III clinical trial is led by Professor Wang Changli from Tianjin Medical University Cancer Institute and Hospital, and carried out in approximately 60 clinical research centers nationwide. It plans to enroll approximately 390 patients with resectable Stage III NSCLC, and the actual number of enrolled patients meets the requirements of the study protocol, successfully completed enrollment ahead of schedule. The core purpose of this study is to evaluate the efficacy and safety of Envafolimab® combined with platinum-containing doublet chemotherapy versus placebo combined with platinum-containing doublet chemotherapy for the neoadjuvant/adjuvant treatment of patients with resectable Stage III NSCLC. The primary endpoints include event-free survival (EFS), pathological response (MPR) rate, and pathological complete response (pCR) rate, etc.

The Company reminds investors that the results of clinical studies are uncertain, and subsequent links such as data statistical analysis, submission of clinical trial reports and drug registration and approval may be affected by various factors, which involves certain risks. The Company will timely disclose the follow-up progress of this clinical trial in accordance with the requirements of the Listing Rules and relevant laws and regulations. Investors are advised to invest prudently and pay attention to investment risks.

By order of the Board
3D Medicines Inc.
Dr. Gong Zhaolong
Chairman of the Board

Hong Kong, May 21, 2026

As at the date of this announcement, the Board of Directors of the Company comprises Dr. GONG Zhaolong as executive Director, Mr. ZHU Jinqiao, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.